Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0113 in Healthy Subjects and Dialysis Patients
NCT02103426Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2013
- Primary completion
- May 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ASP0113 in cytomegalovirus infection (CMV) (10 arms), sponsored by Astellas Pharma. Primary endpoints: ASP0113 plasmids pharmacokinetics in plasma: AUC at Week 25, ASP0113 plasmids pharmacokinetics in plasma: Cmax at Week 25 and 9 more. Started Dec 2013; status: completed.
02
Drugs
ASP0113
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02103426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103426.